Open an account

Pacira Biosciences

PCRX · NASDAQ

$36.38+$0.04 (+0.11%)TodayMarket closed ·
Prev close $36.34

About PCRX

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Brisbane California, California and currently employs 829 full-time employees. The company went IPO on 2011-02-03. The firm has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The firm is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.

Employees
829
Headquarters
Brisbane California, California
Listed
Feb 3, 2011
Sector
Health Care
Industry
Pharmaceuticals
Website
pacira.com

PCRX key statistics

Market cap
1.45B
Price-earnings ratio
103.83
Dividend yield
—
Average volume
2.54M
Volume
1.05M
Open price
$36.39
High today
$36.43
Low today
$36.33
52 Week high
$36.67
52 Week low
$18.80

Pacira Biosciences (PCRX) at a glance

Pacira Biosciences (PCRX) last traded at $36.38, with a market cap of 1.45B and a price-to-earnings ratio of 103.83.

Today the stock has traded between $36.33 and $36.43. The current price is 0.1% above the day's low and 0.1% below its high.

Volume so far is 1.05M shares, below the average of 2.54M shares a day.

Over the past year Pacira Biosciences has ranged from $18.80 to $36.67, and now sits 98% of the way up that range.

Pacira Biosciences met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.73 per share against an estimate of $0.6603.

The average analyst price target is $29.83, 18.0% below the current price, from 8 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

13%of 8 analyst ratings say Buy
  • Buy12.5%
  • Hold87.5%
  • Sell0.0%
Price target · 10 analystsAvg $29.83
Low
$23.23
Now
$36.38
High
$39.90

PCRX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 5.9% on average.

  1. Q3 FY24: reported $0.79 per share against an estimate of $0.7187
  2. Q4 FY24: reported $0.91 per share against an estimate of $0.852
  3. Q1 FY25: reported $0.62 per share against an estimate of $0.6079
  4. Q2 FY25: reported $0.74 per share against an estimate of $0.7245
  5. Q3 FY25: reported $0.70 per share against an estimate of $0.6649
  6. Q4 FY25: reported $0.57 per share against an estimate of $0.9225
  7. Q1 FY26: reported $0.60 per share against an estimate of $0.5746
  8. Q2 FY26: reported $0.73 per share against an estimate of $0.6603

PCRX news

  • Press releasePRNewswire

    Are OPCH, PCRX, RXO, BOLD Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Pacira BioSciences, Inc. (NASDAQ: PCRX)

  • Vandana Singh

    Viatris Bets Big on Non-Opioid Painkillers With Pacira Buyout

  • Press releasePRNewswire

    PCRX SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES PACIRA BIOSCIENCES, INC.

  • Avi Kapoor

    Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings

  • Press releaseBusiness Wire

    PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders

  • Press releasePRNewswire

    Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

Similar companies

Companies in the same industry as Pacira Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.